Science & Enterprise subscription

Follow us on Twitter

  • Nine universities in the U.S. are taking part in a program supporting research and entrepreneurs developing food an… https://t.co/oZ2i6R14UB
    about 3 hours ago
  • New post on Science and Enterprise: Nine Campuses Join Rural Food Research Fund https://t.co/vYlPet30bO #Science #Business
    about 3 hours ago
  • Spark Therapeutics, a developer of gene therapies, is gaining access to a technology that programs DNA sequences li… https://t.co/WGboSsrf7U
    about 1 day ago
  • New post on Science and Enterprise: Gene Therapy Company Exploring DNA Circuit Technology https://t.co/2YUM4DVZRK #Science #Business
    about 1 day ago
  • A study with lab mice shows an experimental vaccine with engineered bacteria produces antibodies and protects again… https://t.co/3JtSqD1Sa2
    about 1 day ago

Please share Science & Enterprise

Infographic – Superbugs Annually Kill 33,000 in Europe

Chart: Superbug deaths n Europe

Click on image for full-size view. (The Lancet, Statista)

10 Nov. 2018. We’ve reported at Science & Enterprise on the problem of antibiotic resistance for several years. Bacteria and viruses evolve into new strains resistant to current antibiotics, also known as “superbugs,” causing health authorities and drug developers to scramble for stronger or alternative options. In some cases, authorities are concerned the development of new antibiotics can’t keep up with new superbug strains, with ominous implications for public health.

Our friends at Statista posted a chart this week that underscores this problem, showing the median number of deaths by country in Europe from microbes resistant to antibiotics, this weekend’s infographic. The data from 2015 first appeared in a paper earlier this month in the medical journal The Lancet, showing some 33,000 died from antibiotic-resistant infections that year. About one-third of those deaths, nearly 11,000, occurred in Italy, with another 5,500 in France.

Researchers on both sides of the Atlantic seem to be taking this threat seriously, and we’ve reported in Science & Enterprise on advances in academic and industry labs to develop new or more powerful diagnostics and antibiotics. A few of the most recent stories are listed below.

More from Science & Enterprise:

*     *     *

Comments are closed.